Antibacterial Drugs: World Market Prospects 2012-2022

What are the commercial prospects for antibacterial treatments? Visiongain's report shows you potential revenue values to 2022. Find data, forecasts and discussions. Discover sales predictions at world market, therapeutic class, product and national levels to 2022. Our report gives you business research, analysis and opinion for the treatment of bacterial infections. How will 20 leading products - including Levaquin, Zyvox, Avelox, Augmentin, Zosyn, Merrem, Cubicin, Primaxin and Cravit - perform to 2022? You can find potential revenues, with discussions. Also, receive forecast values for cephalosporin, penicillin, fluoroquinolone, macrolide and carbapenem submarkets. We analyse other agents too. See possible sales trends for antibiotics from 2012. This study discusses Pfizer, Merck, GSK, Cubist, Abbott, Bayer and other pharmaceutical companies. Receive analyses for anti-infective agents in human healthcare, including hospital-acquired infections. What does the future hold? With its R&D pipeline, the antimicrobial drug industry has potential for improved treatment of bacterial diseases. Bacteria still pose a great threat, with antibiotic resistance staying a challenge in clinical practice. Visiongain's report provides data, analysis and opinion aiming to benefit your research, calculations, meetings and presentations. You can find answers now in our work. Revenue forecasts, market shares, developmental trends, discussions and interviews In our report, you find revenue forecasting, growth rates, market shares, qualitative analyses (incl. SWOT and STEP), views and R&D news. You receive 149 tables and charts and two research interviews. Advantages of Antibacterial Drugs: World Market Prospects 2012-2022 for your work In particular, our study gives you the following knowledge and benefits: Find revenue predictions to 2022 for the overall world antibacterial drug market and submarkets, seeing revenue growth Discover revenue forecasts to 2022 for 20 leading products, assessing commercial potential See revenue forecasts to 2022 for leading national markets - US, Japan, China, India, Brazil, France, Italy, Germany, UK and Spain Assess leading companies, discovering their activities and prospects Review R&D for treating bacterial diseases, seeing pipeline trends Investigate competition and opportunities influencing the sector and its sales Find out what will stimulate and restrain the industry and market View opinions from our survey, discovering interviews with industrial experts. There, you find a distinctive mix of quantitative and qualitative work with independent predictions. We tackle crucial questions on antibacterials, helping you to stay ahead. Gain business research, data and analysis for antibacterial agents

Additional Information

Companies Listed

Abbott Laboratories
Acino
Adimab
Advanced Life Sciences
Agência Nacional de Vigilância Sanitária (Anvisa) [Brazil]
Aisling Capital
Alliance for the Prudent Use of Antibacterials (APUA) [US]
Alopexx Pharmaceuticals
Andrx (now part of Watson Pharmaceuticals)
APP Pharmaceuticals (a subsidiary of Fresenius Kabi)
Arsanis
Astellas Pharma
AstraZeneca
Aurobindo Pharma
Barr Pharmaceuticals (now part of Teva)
Basilea Pharmaceutica
Bayer
Bioquell
C&O Pharmaceutical Technology (Holdings)
Calixa Therapeutics (now part of Cubist Pharmaceuticals)
Canaan Partners
Cempra
Centers for Disease Control and Prevention (CDC) [US]
Centers for Medicare and Medicaid Services (CMS) [US]
Cipla
Copper Development Association [US]
Cornerstone Therapeutics
Cubist Pharmaceuticals
Daiichi Sankyo
Dainippon Sumitomo Pharma
Dr. Reddy's Laboratories
Duke University [US]
Durata Therapeutics
Eli Lilly
EMA Committee for Medicinal Products for Human Use (CHMP)
European Medicines Agency (EMA)
FDA Anti-Infective Drugs Advisory Committee (AIDAC) [US]
Food and Drug Administration (FDA) [US]
Forest Laboratories
Fresenius Kabi Pharmaceuticals
Furiex Pharmaceuticals
Future Path Medical
Gilead Sciences
Glenmark Generics
GSK
Harvard Medical School
Healthcare Infection Control Practices Advisory Committee (HICPAC) [US]
Hikma Farmaceutica
Hospira
Innocell
Insmed
Itochu Chemical Frontier
J&J
Janssen Pharmaceutica (a subsidiary of J&J)
Japan Patent Office (JPO)
KaloBios Pharmaceuticals
Kenta Biotech
King's College London
Lederle Laboratories (acquired by Wyeth, now part of Pfizer)
Lupin Pharmaceuticals
Medicines and Healthcare products Regulatory Agency (MHRA) [UK]
Meiji Seika Kaisha
Merck & Co.
Michigan State University
Ministry of Health and Family Welfare [India]
Ministry of Health, Labor and Welfare (MHLW) [Japan]
Mpex Pharmaceuticals
Mylan
Nanotherapeutics
National Health Service (NHS) [UK]
Nektar Therapeutics
New Leaf Venture Partners
Novartis
Novexel
Optimer Pharmaceuticals
Orchid Chemicals and Pharmaceuticals
Ortho-McNeil Pharmaceuticals (a subsidiary of J&J)
Oscient Pharmaceuticals
Paratek Pharmaceuticals
Parke-Davis (now part of Pfizer)
Peking University
Pfizer
Pharmaceutical Research and Manufacturers of America (PhRMA) [US]
Pharmacia (now part of Pfizer)
Pliva (now part of Teva)
RaQualia Pharma
Rib-X Pharmaceuticals
Roche
Sandoz
Sanofi
Sanofi Pasteur (part of Sanofi)
Sawai Pharmaceutical
Schering-Plough (now part of Merck & Co)
Shionogi
St Thomas' Hospital
Strides Arcolab
Sumitomo Pharmaceuticals (now part of Dainippon Sumitomo)
Takeda Pharmaceutical Company
TAP Holdings
Targanta Therapeutics (now part of The Medicines Company)
Teva Pharmaceuticals
The Medicines Company
Theravance
Trius Therapeutics
University of Birmingham [UK]
University of Pennsylvania
US Department of Defense
Vicuron Pharmaceuticals (now part of Durata Therapeutics)
Watson Pharmaceuticals
Wockhardt
World Health Organization (WHO)
Wyeth (now part of Pfizer)